Cipher Pharmaceuticals Inc  

(Public, TSE:CPH)   Watch this stock  
Find more results for TSE:DND
4.50
-0.05 (-1.10%)
Feb 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.50 - 4.50
52 week 3.50 - 8.18
Open 4.50
Vol / Avg. 0.00/21,912.00
Mkt cap 116.97M
P/E     -
Div/yield     -
EPS -1.27
Shares 26.31M
Beta 0.20
Inst. own     -
Feb 22, 2017
Q4 2016 Cipher Pharmaceuticals Inc Earnings Release (Estimated)
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -235.14% 5.14%
Operating margin -223.71% -0.20%
EBITD margin - 14.50%
Return on average assets -89.06% 2.01%
Return on average equity -219.90% 3.27%
Employees 90 -
CDP Score - -

Address

2345 Argentia Rd Suite 100A
MISSISSAUGA, ON L5N 8K4
Canada
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links

Description

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Officers and directors

John D. Mull M.D. Chairman of the Board
Age: 83
Stephen L. Lemieux CPA President, Interim Chief Executive Officer, Chief Financial Officer, Secretary
Ralph Bohrer President and General Manager of US Business
Age: 54
Joan Chypyha President, General Manager - Canada
Joseph Pecora President and General Manager - USA
Lorne Markowitz Vice President of Sales and Marketing
Linda Melanie Angaritis Vice President - Global Regulatory Compliance and Quality
Louise Blythe Vice President - Regulatory Affairs
Lynne Cheryl Bulger Vice President - Medical and Clinical Affairs
Brian Rosenberger Vice President - Alliance and Strategic Portfolio Management